Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography.
Positron Emission Tomography (PET) offers an exciting opportunity to monitor key pathways involved in malignant transformation due to the ability to radiolabel and image the behaviour of biological probes. In this review, we will describe how PET can use various radiolabelled compounds to monitor various targets including ligand-receptor interactions using 16alpha-[(18)F]fluoro-17beta-oestradiol (FES) pathways involved in metabolism with [(18)F]fluorodeoxy-glucose ([(18)F]FDG), (11)C-methyl-choline for signal transduction, cell cycle and proliferation with 2-[(11)C]thymidine, cell death using [(124)I]annexin V, [(124)C]colchicine for drug resistance and angiogenesis using [(124)I]anti-VEGF.
Hutchinson
O Clyde
OC
Cancer Research UK, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
Collingridge
David R
DR
Barthel
Henryk
H
Price
Pat M
PM
Aboagye
Eric O
EO
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy; D011849:Radioactive Tracers; D019275:Radiopharmaceuticals / Q000494:pharmacology*; D014055:Tomography, Emission-Computed
D000970:Antineoplastic Agents; D011849:Radioactive Tracers; D019275:Radiopharmaceuticals